Pharmaceutical

Lenvatinib mesylate by Eisai for Metastatic Biliary Tract Cancer: Likelihood of Approval

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Metastatic Biliary Tract Cancer.

Dec 24, 2023 - 18:00
Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Metastatic Biliary Tract Cancer.
Read the original article

Tags:

Previous Article

STAT+: FDA approves AstraZeneca, Ionis treatment for rare nerve disease

Next Article

Mecbotamab vedotin by BioAtla for Breast Cancer: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Ipsen’s Elafibranor gains MHRA approval for PBC treatment

Ipsen’s Elafibranor gains MHRA approval for PBC treatment

Oct 10, 2024

Sanofi and AstraZeneca to supply additional RSV doses to US

Sanofi and AstraZeneca to supply additional RSV doses t...

Dec 16, 2023

Opinion: STAT+: The necessary roughness of 2023 has set up a very promising 2024 for biotech jobs

Opinion: STAT+: The necessary roughness of 2023 has set...

Jan 20, 2024